wenn sie dieses Patent bekommen ? ( letzter Satz )
HRC 304 - Blood Cell Production
Hemosol Research Corporation Ltd. (HRC) scientists have recently discovered that stem cells possess a novel activation pathway that may play a role in blood cell production. Stimulation of stem cells via this pathway in vitro produces an increase in the growth of red blood cell and white blood cell progenitors.
Treatment of Anemia and Other Cytopenias
The discovery of a new stem cell activation pathway offers HRC the opportunity to develop novel therapeutics for the treatment of anemia. At present, erythropoietin (Epo) is the most well known therapeutic cytokine used for the treatment of anemia, acting through the selective stimulation of red blood cell production. Epo has an established North American market on the order of $1 B (USD) and is widely held as the gold standard for biotechnology companies in terms of both drug development and corporate success. Other cytokines have been developed for stimulating blood cell formation but none compare with the success of Epo (or its newer long acting version, darbepoietin). Even so, many patients, particularly those experiencing anemia while undergoing chemotherapy for the treatment of cancer and those with anemia of chronic disease, do not respond to Epo.
Clearly, an alternative pathway for stimulating the production of red blood cells, and potentially even white blood cells, offers tremendous opportunity for the development of new drugs in a large, proven market with an important medical need. HRC's expertise in stem cell research places it in good position to capitalize on this important new discovery.
Intellectual Property Covering HRC 304
Patent applications are pending.
CIAO
